899 completed. 899 Phase 2, 211 Phase 1, 16 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 899 | Completed 899 |
| Phase 1 | 211 | Completed 211 |
| Phase 3 | 16 | Completed 16 |
Follow Hemostatic Disorders: new trials by email Literature Review of Hemostatic Disorders trials Research Report on Hemostatic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz) Pazopanib, Placebo oral capsule - Hereditary Hemorrhagic Telangiectasia, Epistaxis | Phase 2 / Phase 3 | Completed | Cure HHT | 71 | 2023-05-08 | 2026-10-27 |
| Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant GPC-100, Propranolol, G-CSF - Multiple Myeloma | Phase 2 | Completed | GPCR Therapeutics, Inc. | 30 | 2023-02-13 | 2026-02-12 |
| A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum DS-1211b, Placebo - Pseudoxanthoma Elasticum | Phase 2 | Completed | Daiichi Sankyo | 65 | 2022-10-20 | 2024-12-31 |
| SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease Selinexor, Bortezomib, Lenalidomide - Multiple Myeloma | Phase 2 | Completed | The First Affiliated Hospital with Nanjing Medical University | 29 | 2022-07-15 | 2026-09-02 |
| Phase I Trial of GR1803 Injection in Patients With RRMM GR1803 injection - Multiple Myeloma (MM) | Phase 1 / Phase 2 | Completed | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 76 | 2022-05-27 | 2025-08-05 |
| A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma Cilta-cel, Lymphodepleting Therapy (Cyclophosphamide and Fludarabine) - Multiple Myeloma | Phase 2 | Completed | Janssen Scientific Affairs, LLC | 86 | 2022-05-13 | 2025-04-25 |
| Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE INZ-701 - ATP-Binding Cassette Subfamily C Member 6 Deficiency, Pseudoxanthoma Elasticum | Phase 1 / Phase 2 | Completed | Inozyme Pharma | 10 | 2022-04-11 | 2026-10-13 |
| Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant Pegfilgrastim - Myeloma Multiple, Lymphoma | Phase 2 | Completed | Hospital Universitario Dr. Jose E. Gonzalez | 30 | 2022-04-01 | 2023-02-28 |
| The Symptomatic Cerebral Cavernous Malformation Trial of REC-994 REC-994, Placebo - Cerebral Cavernous Malformation | Phase 2 | Completed | Recursion Pharmaceuticals Inc. | 62 | 2022-03-17 | 2026-10-22 |
| Sirolimus for Nosebleeds in HHT Sirolimus - Hereditary Hemorrhagic Telangiectasia, Nosebleeds | Phase 2 | Completed | Unity Health Toronto | 10 | 2022-03-16 | 2026-06-04 |
| Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma Belantamab mafodotin - Multiple Myeloma | Phase 2 | Completed | GlaxoSmithKline | 177 | 2022-03-03 | 2026-05-05 |
| Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma Lenalidomide, bb2121, Cyclophosphamide - Multiple Myeloma | Phase 2 | Completed | Medical College of Wisconsin | 40 | 2022-01-05 | 2026-05-19 |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. Elranatamab - Elranatamab, Myeloma | Phase 2 | Completed | Pfizer | 39 | 2021-12-21 | 2026-09-29 |
| Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer Curcumin plus Piperine - Prostate Cancer, Multiple Myeloma | Phase 2 | Completed | University of Rochester | 30 | 2021-12-14 | 2026-05-12 |
| Safety and Feasibility of Argatroban As Anticoagulant in Adults with ECMO Argatroban, Unfractionated heparin - Extracorporeal Membrane Oxygenation Complication, Anticoagulants and Bleeding Disorders | Phase 2 / Phase 3 | Completed | Medical University of Vienna | 40 | 2021-12-01 | 2024-09-19 |
| Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy Siltuximab - Cytokine Release Syndrome, ICANS | Phase 2 | Completed | University of Alabama at Birmingham | 20 | 2021-11-15 | 2026-07-27 |
| A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment Elranatamab - Multiple Myeloma | Phase 2 | Completed | Pfizer | 86 | 2021-10-07 | 2026-02-10 |
| A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma KRN125(pegfilgrastim), PLR001(plerixafor), KRN8601(filgrastim), PLR001(plerixafor) - Multiple Myeloma and Malignant Lymphoma | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 64 | 2021-09-01 | 2023-02-21 |
| COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies A single "booster" dose of the Moderna mRNA COVID-19 vaccine - Multiple Myeloma, AL Amyloidosis | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 119 | 2021-08-17 | 2023-12-20 |
| REST - Replacing Steroids in the Transplant Ineligble Isatuximab, bortezomib, lenalidomide, dexamethason - Multiple Myeloma | Phase 2 | Completed | Oslo University Hospital | 51 | 2021-06-29 | 2025-03-20 |
Showing 20 of 899. Sign in to see all of them.
Multiple Myeloma (747) · Neoplasms, Plasma Cell (176) · Lymphoma, Non-Hodgkin (172) · Leukemia, Lymphocytic, Chronic, B-Cell (168) · Waldenstrom Macroglobulinemia (152) · Lymphoma, Follicular (141) · Hodgkin Disease (136) · Lymphoma (134) · Lymphoma, B-Cell, Marginal Zone (134) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (125) · Lymphoma, Mantle-Cell (122) · Lymphoma, Large B-Cell, Diffuse (106) · Leukemia (104) · Recurrence (102) · Burkitt Lymphoma (100)
Hemic and Lymphatic Diseases (899) · Cardiovascular Diseases (898) · Vascular Diseases (898) · Hemorrhagic Disorders (895) · Hematologic Diseases (886) · Neoplasms by Histologic Type (854) · Blood Protein Disorders (852) · Immune System Diseases (852) · Immunoproliferative Disorders (852) · Paraproteinemias (848) · Lymphoproliferative Disorders (843) · Neoplasms (833) · Neoplasms, Plasma Cell (676) · Lymphatic Diseases (297)
Dexamethasone (226) · Cyclophosphamide (141) · Bortezomib (136) · Lenalidomide (130) · Melphalan (111) · Calcium Dobesilate (74) · Peripheral Blood Stem Cell Transplantation (71) · fludarabine phosphate (61) · Filgrastim (52) · Rituximab (49) · Thalidomide (48) · Mycophenolic Acid (47) · Busulfan (45) · carfilzomib (42) · Tacrolimus (41)
Fred Hutchinson Cancer Center (48) · Mayo Clinic (46) · National Cancer Institute (NCI) (40) · Memorial Sloan Kettering Cancer Center (27) · M.D. Anderson Cancer Center (24) · Dana-Farber Cancer Institute (21) · University of Arkansas (18) · Celgene (16) · H. Lee Moffitt Cancer Center and Research Institute (15) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (15) · Amgen (12) · Janssen Research & Development, LLC (11) · University of Michigan Rogel Cancer Center (10) · Case Comprehensive Cancer Center (9) · City of Hope Medical Center (9)
United States (647) · Canada (67) · France (66) · Germany (63) · Italy (57) · Spain (47) · United Kingdom (44) · Greece (27) · Netherlands (27) · Australia (25) · Japan (22) · Austria (19) · Belgium (19) · Denmark (19) · Poland (17)
Brenda Sandmaier (8) · Shaji Kumar (6) · William I. Bensinger, MD (6) · Christos E. Emmanouilides, MD (5) · David Maloney (5) · Irene Ghobrial, MD (5) · Ivan Borrello, MD (5) · Leona Holmberg (5)
PMID 32499241, PMID 35549810, PMID 31221778, PMID 40156952, PMID 20661232, PMID 25628469, PMID 26181891, PMID 26308596, PMID 26690712, PMID 27307294, PMID 29025767, PMID 30536810, PMID 30957581, PMID 32107329, PMID 32470437, PMID 34465265, PMID 35132679, PMID 37022569, PMID 37934000, PMID 38649340, PMID 40000533, PMID 40471585, PMID 40674744, PMID 40826257, PMID 42287565, PMID 10084252, PMID 10414913, PMID 10414914, PMID 10459351, PMID 10482933, PMID 10564685, PMID 10918404, PMID 12000194, PMID 12473574, PMID 12663715, PMID 12738671, PMID 14508361, PMID 14767498, PMID 15156165, PMID 15241836, PMID 15308571, PMID 15370249, PMID 15493038, PMID 15623591, PMID 15867202, PMID 15880129, PMID 15902208, PMID 15911237, PMID 15958804, PMID 16398649
P30CA015083 (30), P30CA015704 (19), 2017 (12), P30CA006973 (10), 2008 (8), U10CA032102 (8), 2005 (7), P01CA078902 (7), 2009 (6), 2015 (6), 2018 (6), P01CA018029 (6), 2014 (5), U10CA031946 (5), 2016 (4)